Abstract:
본 발명은 뇌에서 mPTP의 작용을 선택적으로 억제하여 미토콘드리아의 기능을 향상시키는 신경보호제로서 작용하여 중추신경계 질환의 치료 또는 예방제로 효과를 보이는 유레아 유도체 또는 이의 약제학적으로 허용 가능한 염, 이들 화합물의 제조방법, 그리고 이들 화합물이 유효성분으로 함유된 약학조성물에 관한 것이다.
Abstract:
PURPOSE: A urea derivative is provided to selectively suppress the action of mPTP in the brain, thereby being used as a neuroprotective agent which improves the action of the mitochondria. CONSTITUTION: A urea derivative is denoted by chemical formula 1. A method for preparing the urea derivative comprises the steps of making a compound of chemical formula 2 react with isocyanate compounds or isothiocyanate compounds. The compound of chemical formula 2 is prepared by making a compound of chemical formula 3 react with benzyl halide compounds. A pharmaceutical composition for suppressing the action of mPTP contains the urea derivative or a pharmaceutically acceptable salt thereof as an active ingredient. A pharmaceutical composition for treating nervous diseases contains the urea derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
Abstract:
A composition which contains caffeine, its analog, or its pharmaceutically allowable salt is provided to suppress infiltration, metastasis, and proliferation and prevent and/or treat brain cancer. A composition for preventing and treating brain cancer comprises caffeine, caffeine anaolog, or its pharmaceutically allowable salt as an active ingredient. The caffeine, caffeine analog or its pharmaceutically allowable salt has the content of 0.3-30 mM. The daily dose of the composition is 1-5 mg/kg and the composition is administered at one time or several times. The brain cancer is glioma, exothelioma, pituitary adenoma, schwannoma, craniopharyngioma or the congenital brain tumor. The composition selectively block the subtype 3 of activation of inositol-1,4,5-triphosphate receptoer(IP3R).
Abstract:
본 발명은 단가아민 재흡수 억제 활성을 보이는 (1S,3aR,9bS)-1-페닐-2,3,3a,4,5,9b-헥사하이드로-1H-벤조[e]인돌 유도체와 3,4-다이아릴피롤리딘-2-온 유도체, 이들 화합물의 제조방법, 그리고 이들 화합물이 유효성분으로 함유된 약학적 조성물에 관한 것이다.
Abstract:
PURPOSE: A pharmaceutical composition containing a novel 1-(4-halophenyl oxo or thio)-3-(4-substituted piperazine-1-yl)propane-2-ol derivative is provided to effectively suppress T type calcium channel activation and to prevent or treat hypertension, cancer, epilepsy, and neurogenic pain. CONSTITUTION: A novel 1-(4-halophenyl oxo or thio)-3-(4-substituted piperazine-1-yl)propan-2-ol derivative is denoted by chemical formula 1. A method for preparing the compound of chemical formula 1 comprises: a step of reacting a compound of chemical formula 2 with chiral epichlorohydrin under the presence of a base and solvent to prepare an epoxy compound of chemical formula 3; and a step of reacting the epoxy compound of chemical formula 3 with piperazine derivative of chemical formula 4. The base is potassium carbonate, sodium carbonate or pyridine. A pharmaceutical composition for preventing or treating diseases caused by overactivation of T type calcium channel contains the derivative or pharmaceutically acceptable salt thereof as an active ingredient.